JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors

Authors: Kathryn A. F. Pennel, Phimmada Hatthakarnkul, Colin S. Wood, Guang-Yu Lian, Sara S. F. Al-Badran, Jean A. Quinn, Assya Legrini, Jitwadee Inthagard, Peter G. Alexander, Hester van Wyk, Ahmad Kurniawan, Umar Hashmi, Michael A. Gillespie, Megan Mills, Aula Ammar, Jennifer Hay, Ditte Andersen, Colin Nixon, Selma Rebus, David K. Chang, Caroline Kelly, Andrea Harkin, Janet Graham, David Church, Ian Tomlinson, Mark Saunders, Tim Iveson, Tamsin R. M. Lannagan, Rene Jackstadt, Noori Maka, Paul G. Horgan, Campbell S. D. Roxburgh, Owen J. Sansom, Donald C. McMillan, Colin W. Steele, Nigel B. Jamieson, James H. Park, Antonia K. Roseweir, Joanne Edwards

Source: Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-20 (2024)

Subject Terms: Colorectal cancer, Cellular signaling, JAK/STAT3 signal transduction, Tumor microenvironment, Prognosis, Spatial biology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1756-9966

Access URL: https://doaj.org/article/3b63169b435447a19a5fb490ee037279